Stockscreener 앱 받기
7.30
6.05%
-0.47
시간 외 거래:
7.26
-0.04
-0.55%
4 D Molecular Therapeutics Inc 주식(FDMT)의 최신 뉴스
Why 4D Molecular Therapeutics Inc. stock appeals to dividend seekersMarket Weekly Review & Low Drawdown Investment Strategies - ulpravda.ru
Can 4D Molecular Therapeutics Inc. stock double in next 5 years2025 Analyst Calls & Daily Technical Stock Forecast Reports - ulpravda.ru
Is 4D Molecular Therapeutics Inc. stock a buy on dipsJuly 2025 Setups & Free Long-Term Investment Growth Plans - ulpravda.ru
Is 4D Molecular Therapeutics Inc. stock a top momentum play2025 Volatility Report & High Accuracy Swing Trade Signals - ulpravda.ru
Will 4D Molecular Therapeutics Inc. stock gain from strong economyPrice-to-Book Ratio Updates & Budget Friendly Portfolio Growth - ulpravda.ru
4D Molecular Therapeutics, Inc. Announces Executive Changes - MarketScreener
4DMT Provides Company Update and Anticipated Development Milestones for 2026 - The Manila Times
2026 world cup analysis rankings: Will 4D Molecular Therapeutics Inc. stock gain from strong economy2026 world cup usa national team round of 32 defensive leaders counter attacking winner prediction expert opinion - ulpravda.ru
Certain Options of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-JAN-2026. - marketscreener.com
Certain Common Stock of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-JAN-2026. - MarketScreener
4D Molecular falls after early-stage trial data for cystic fibrosis therapy - MSN
Why Everyone Is Watching 4D Molecular Therapeutics, Inc. (FDMT) Closely - Finviz
Ashoo Gupta of 4D Molecular Therapeutics sells $3.3k in FDMT stock - Investing.com Australia
4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) institutional investors lost 20% over the past week but have profited from longer-term gains - Yahoo Finance
4D Molecular Therapeutics Gains Momentum from Clinical Data and Index Inclusion - AD HOC NEWS
4D Molecular Therapeutics, Inc.(NasdaqGS:FDMT) added to S&P Biotechnology Select Industry Index - marketscreener.com
How interest rate cuts could boost 4D Molecular Therapeutics Inc. stockJuly 2025 Chart Watch & Accurate Buy Signal Notifications - Улправда
Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and 4D Molecular Therapeutics (FDMT) - The Globe and Mail
Is 4D Molecular Therapeutics Inc. stock ready for breakoutJuly 2025 Weekly Recap & Long Hold Capital Preservation Plans - Улправда
4D Molecular Therapeutics Executive Sells Shares - TradingView — Track All Markets
4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop (NASDAQ:FDMT) - Seeking Alpha
Analysts Are Bullish on Top Healthcare Stocks: Novan (NOVN), 4D Molecular Therapeutics (FDMT) - The Globe and Mail
What insider trading reveals about 4D Molecular Therapeutics Inc. stockQuarterly Portfolio Report & AI Powered Trade Plan Recommendations - DonanımHaber
Analysts Are Bullish on Top Healthcare Stocks: 4D Molecular Therapeutics (FDMT), Novan (NOVN) - The Globe and Mail
Stock Market Recap: Is 4D Molecular Therapeutics Inc. stock a top momentum playQuarterly Portfolio Report & Accurate Buy Signal Notifications - DonanımHaber
4D Molecular Therapeutics (NASDAQ:FDMT) Given “Buy” Rating at Chardan Capital - Defense World
Chardan Capital Maintains 4D Molecular Therapeutics (FDMT) Buy Recommendation - Nasdaq
What dividend safety score for 4D Molecular Therapeutics Inc. stockJuly 2025 Action & Long-Term Investment Growth Plans - Улправда
4D Molecular Therapeutics : 710 AEROW Interim Phase 1 Data & Program Update (610855) - marketscreener.com
4D Molecular posts Phase 1 trial data for cystic fibrosis drug - Seeking Alpha
4D Molecular Therapeutics Announces Positive Interim Clinical Data from 4D-710 Aerow Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease - marketscreener.com
4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform PotentialSlideshow (NASDAQ:FDMT) 2025-12-17 - Seeking Alpha
4D Molecular Therapeutics Reports Positive Interim Phase 1 Data For 4D-710 In Cystic Fibrosis - Nasdaq
4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease - Yahoo Finance
Officer Bizily Files To Sell 1,635 Of 4D Molecular Therapeutics Inc [FDMT] - TradingView — Track All Markets
4D Molecular Therapeutics (FDMT) director reports 9,333-share option exercise - Stock Titan
4DMT Announces New Employment Inducement Grants - Sahm
4D Molecular Therapeutics (Nasdaq: FDMT) Issues 13,800 RSUs Under 2025 Inducement Plan - Stock Titan
4D Molecular Therapeutics expands phase 3 trial enrollment - MSN
4D Molecular Therapeutics grants CFO option on 480,000 FDMT shares | FDMT SEC FilingForm 4 - Stock Titan
4D Molecular Therapeutics (FDMT) CFO reports no securities holdings - Stock Titan
4D Molecular Therapeutics Expands Phase 3 Trial Enrollment - TipRanks
4D Molecular Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
4D Molecular Therapeutics Advances in Macular Degeneration Treatment: A Phase 3 Study Update - MSN
4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Decheng Capital LLC - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Shares Down 7.4%Here's What Happened - MarketBeat
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates - MSN
4D Molecular Therapeutics Reports Strategic Gains in Q3 2025 - MSN
4D Molecular Therapeutics taps Kristian Humer as CFO - MSN
0.80%
4.56%
자본화:
|
볼륨(24시간):